Oncternal Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Oncternal Therapeutics, Inc.
Finance Watch: Lucky Few Raise Cash While Many Public Biotechs Cut Costs
Public Company Edition: ImmunoGen received the first $75m under a $175m term loan, while Protagonist raised $100m in a follow-on offering, but companies with bankruptcy filings and job cuts outpaced those accessing new capital by a wide margin in late March and early April.
Deal Watch: Appili Gets AiPharma’s Help In Advancing COVID-19 Therapy
Appili brings in AiPharma to help with US/Canadian development of Fujifilm’s potential COVID-19 preventative/therapeutic. Other recent tie-ups include CinFina/Janssen, Bone/Impant, Bayer/Gubra, Novartis/Theragnostics, Grifols/Biotest and more.
Tech Transfer Roundup: MD Anderson Tackles Cancer In Alliances With UroGen, Xencor, Obsidian
In tandem with buying the rest of Kleo, Tonix licenses molecular degradation technology from Yale. Neurogene, University of Dundee partner on cell therapies for neurological disorders.
Merck & Co. Looks To Artiva’s Off-The-Shelf Cell Therapy Technologies
Deal Snapshot: Pharma places $30m upfront wager on biotech’s allogeneic natural killer cell and chimeric antigen receptor technologies, with hopes for solid tumor cell therapies.
- Large Molecule
- Other Names / Subsidiaries
- GTx, Inc.
- Tokalas, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.